JP6616631B2 - TNF-α production promoter - Google Patents
TNF-α production promoter Download PDFInfo
- Publication number
- JP6616631B2 JP6616631B2 JP2015171689A JP2015171689A JP6616631B2 JP 6616631 B2 JP6616631 B2 JP 6616631B2 JP 2015171689 A JP2015171689 A JP 2015171689A JP 2015171689 A JP2015171689 A JP 2015171689A JP 6616631 B2 JP6616631 B2 JP 6616631B2
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- fermentation
- kale
- production
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000006433 tumor necrosis factor production Effects 0.000 title claims description 46
- 240000007124 Brassica oleracea Species 0.000 claims description 48
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 48
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 48
- 238000000855 fermentation Methods 0.000 claims description 48
- 230000004151 fermentation Effects 0.000 claims description 47
- 230000001737 promoting effect Effects 0.000 claims description 27
- 239000000047 product Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 27
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 24
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 235000000346 sugar Nutrition 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 11
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 239000002609 medium Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000010564 aerobic fermentation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102000003390 tumor necrosis factor Human genes 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100031111 Disintegrin and metalloproteinase domain-containing protein 17 Human genes 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 108091007505 ADAM17 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 102000010183 Bradykinin receptor Human genes 0.000 description 1
- 108050001736 Bradykinin receptor Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- -1 brown sugar Chemical compound 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000001471 micro-filtration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000001967 plate count agar Substances 0.000 description 1
- 239000001965 potato dextrose agar Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000012773 waffles Nutrition 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明は、TNF−α分泌促進作用を有するケール由来の発酵組成物に関する。 The present invention relates to a kale-derived fermentation composition having TNF-α secretion promoting action.
腫瘍壊死因子(Tumor Necrosis Factor, TNF)とは、サイトカインの1種であり、狭義にはTNF−α、TNF−β(リンホトキシン(LT)-α)およびLT−βの3種類である。TNF−αは主にマクロファージにより産生され、固形がんに対して出血性の壊死を生じさせるサイトカインとして発見された。腫瘍壊死因子といえば一般にTNF−αを指している。本発明においても、TNFと略記する場合は、TNF−αを意味する。TNF−αはマウスに移植した腫瘍に対して出血性壊死を誘発させる因子として1975年に単離され、1984年に遺伝子がクローニングされた。TNF−αは分子量25kDaの前駆体タンパク質である膜結合型TNF−α(mTNF−α)として産生されるが、TNF−α変換酵素(TACE)により細胞外に存在するカルボキシル基側末端ドメインの切断を受けて17kDaの可溶性TNF−α(sTNF−α)タンパク質(157アミノ酸残基)となる。mTNF−αとsTNF−αのいずれも活性を有する。さらにTNF−αは51kDaのホモ3量体を形成し、血液中を循環する。TNF−αは主に活性化されたマクロファージによって産生される他、単球、T細胞やNK細胞、平滑筋細胞、脂肪細胞も産生源となる。このようなTNF−αの分泌を促進する医薬品や食品が知られている。生体や免疫細胞のTNF−α産生を促進することができれば、免疫力の向上や感染治療などに有効である。
特許文献1には大豆蛋白質の酵素分解物が免疫促進効果を有していること、そしてその中に含まれる特定の配列を有するペプチドがTNF−α分泌を促進することが記載されている。
Tumor necrosis factor (TNF) is one kind of cytokine, and in a narrow sense, TNF-α, TNF-β (lymphotoxin (LT) -α) and LT-β. TNF-α is mainly produced by macrophages and was discovered as a cytokine that causes hemorrhagic necrosis for solid tumors. Speaking of tumor necrosis factor generally refers to TNF-α. Also in the present invention, the abbreviation TNF means TNF-α. TNF-α was isolated in 1975 as a factor that induces hemorrhagic necrosis in tumors transplanted into mice, and the gene was cloned in 1984. TNF-α is produced as a membrane-bound TNF-α (mTNF-α), which is a precursor protein with a molecular weight of 25 kDa, but is cleaved by the TNF-α converting enzyme (TACE) on the carboxyl side terminal domain existing outside the cell. To 17 kDa soluble TNF-α (sTNF-α) protein (157 amino acid residues). Both mTNF-α and sTNF-α have activity. Furthermore, TNF-α forms a 51 kDa homotrimer and circulates in the blood. In addition to being produced mainly by activated macrophages, TNF-α is also the source of production of monocytes, T cells, NK cells, smooth muscle cells, and adipocytes. Such pharmaceuticals and foods that promote secretion of TNF-α are known. If TNF-α production by living bodies and immune cells can be promoted, it is effective for improving immunity and treating infection.
一方、野菜類の搾り汁である野菜飲料は、各種ビタミン、ミネラルを豊富に含むため、消費者の野菜不足への意識や健康志向の高まりに伴い、その需要が増大している。特にケールの搾汁液である青汁に代表される緑色野菜を含有した飲料は、年々その消費が拡大している。特にケールの青汁には、種々の生理活性を有することが知られており、生理的な作用を期待して飲用される。例えばケールの免疫に関わる生理作用としては、インターロイキン4抑制作用(特許文献2)、ブラジキニン受容体拮抗作用(特許文献3)、抗アレルギー・抗炎症作用(特許文献4)などが知られている。
また、ケールなどの青汁と乳酸菌を併用することで便秘改善作用を付与した食品を調製する方法(特許文献5)や乳酸菌により青汁を発酵させて異臭を改善する方法(特許文献6)などのケールの加工技術が知られている。
On the other hand, vegetable beverages, which are squeezed vegetable juices, are rich in various vitamins and minerals, and therefore demand is increasing as consumers become more aware of vegetable shortages and health-conscious. In particular, consumption of beverages containing green vegetables typified by green juice, which is the juice of kale, is increasing year by year. In particular, kale green juice is known to have various physiological activities, and is drunk in anticipation of physiological effects. For example, as physiological actions related to Kale's immunity, interleukin 4 inhibitory action (Patent Document 2), bradykinin receptor antagonistic action (Patent Document 3), anti-allergy / anti-inflammatory action (Patent Document 4) and the like are known. .
Moreover, the method of preparing the food which gave the constipation improvement action by using together green juice, such as a kale, and lactic acid bacteria (patent document 5), the method of fermenting green juice with lactic acid bacteria, and improving a bad smell (patent document 6), etc. Kale processing technology is known.
本発明は、TNF−α産生促進作用を有するケール由来の発酵物を得ることを課題とする。 This invention makes it a subject to obtain the fermented material derived from Kale which has a TNF- (alpha) production promotion effect.
本発明者は、ケールを原料とする発酵食品を製造する過程で、ケールの発酵産物が免疫細胞のTNF−α産生能を向上させることを見いだし、本発明を提案するものである。 The present inventor has found that the fermentation product of kale improves the TNF-α production ability of immune cells in the process of producing fermented foods using kale as a raw material, and proposes the present invention.
本発明の主な構成は次のとおりである。
(1)ケールと糖類からなる混合物を発酵させた後、得られた発酵物を遠心分離して得られる沈殿物を有効成分とするTNF−α産生促進剤。
(2)発酵の最終pHが4以下である(1)に記載のTNF−α産生促進剤。
(3)下記の工程からなるTNF−α産生促進剤の製造方法。
1)ケール葉を常在菌が残留するように軽度に水洗する工程
2)ケール葉を裁断する工程
3)ケール葉の水分量に相当する質量の糖類と混合し、好気性〜通性嫌気性条件で発酵させる工程
4)発酵終了後、固形物をろ過して除去し、TNF−α産生促進活性を有するろ過液を回収する工程
5)遠心分離を行い、沈殿物を回収する工程
The main configuration of the present invention is as follows.
(1) A TNF-α production promoter comprising a precipitate obtained by fermenting a mixture of kale and saccharide and then centrifuging the obtained fermented product as an active ingredient.
(2) The TNF-α production promoter according to (1), wherein the final pH of fermentation is 4 or less.
(3) A method for producing a TNF-α production promoter comprising the following steps.
1) Step of washing the kale leaf with light so that resident bacteria remain 2) Step of cutting the kale leaf 3) Mixing with a saccharide having a mass corresponding to the water content of the kale leaf, aerobic to facultative anaerobic Step of fermenting under conditions 4) Step of recovering a filtrate having TNF-α production promoting activity by filtering and removing solid matter after completion of fermentation.
5) Step of collecting precipitates by centrifugation
新たなTNF−α産生促進剤が提供される。このTNF−α産生促進剤は、感染症や癌などの予防治療剤として利用可能である。 A new TNF-α production promoter is provided. This TNF-α production promoter can be used as a preventive or therapeutic agent for infectious diseases and cancer.
本発明は、ケールと糖類の混合物を発酵させた発酵物を有効成分とするTNF−α産生促進剤に関する。
発酵にあたっては、好気性〜通性嫌気性発酵させる。発酵方法は、特開平9−294560号に公報に1次発酵方法として開示されている手法を採用することができる。なおこの先行技術の発酵方法は、通性好気発酵を行うために、植物原料に黒糖を添加する操作は同一であるが、先行技術は、さらに酵母を添加して発酵させる点で本発明の手法とは異なる。
より具体的には、次の方法を例示することができる。
まずケールとケールに含有されている水分量と同量の糖類を混合する。この混合物を暫時静置し、ケール中の水分や蛋白質等の各種成分を滲出させながらケールに常在している微生物(または常在菌)によって、通性好気性条件にて自然発酵させる。
発酵させるための操作手順としては、まず十分成熟したケールの葉を採取し、次いで前処理として、採取した葉を収穫後軽く水で洗浄し、水気を切り、また傷や腐敗した部分は予め切除する。ケールは、カッターや裁断機を用いて1〜5cm程度の大きさに切断する。かくして裁断されたケール葉を、発酵容器中でケールに含まれる水分量と同量の糖類と混合して、重石を載せ、発酵の初期はケールに常在する微生物(常在菌)による通性好気性発酵を行わせる。ケールと混合する糖類は、黒糖、三温糖、精白糖、グラニュー糖などショ糖を主成分とする糖類が好ましく、黒糖が特に好ましい。またケール中の水分量は、予め測定するか、5訂食品標準成分表に開示されている水分量と同量(約90%相当)を混合する。ケールに含有されている各種成分や蛋白質などが、糖類と混合すると浸透圧によって抽出される。これらの成分が発酵によりTNF−α産生促進作用を有する組成物へと変換されるものと考えられる。なおケールの5訂食品標準成分表に基づく水分量は、100gあたり90.2gであるので、ケールの水分量を測定しない場合は、ケール重量の90%重量を目途として糖類を配合すればよい。
発酵容器中では、通性好気性発酵条件を維持するため、蓋の上に、重し(重石)を載せて静置する。重しの重量は、100平方センチ当たり0.2〜2kgとする。発酵開始時は1日1回〜数回撹拌を行い、その後25〜35℃の温度を維持しながら2〜10ヶ月間好気性発酵を持続させる。この発酵過程では、主としてケールに常在する微生物(常在菌)による発酵が同時進行し、発酵過程でケールの組織が酵素分解を受けて、液体と固体の混在する粘質性のケール発酵物となる。このケール発酵物を金網等でろ過することで、本発明の目的物であるTNF−α産生促進作用を有するケール発酵物を得る。
The present invention relates to a TNF-α production promoter containing a fermented product obtained by fermenting a mixture of kale and sugar as an active ingredient.
In the fermentation, aerobic to facultative anaerobic fermentation is performed. As a fermentation method, a technique disclosed in Japanese Patent Application Laid-Open No. 9-294560 as a primary fermentation method can be employed. In this prior art fermentation method, in order to perform facultative aerobic fermentation, the operation of adding brown sugar to the plant raw material is the same, but the prior art further adds yeast to ferment and further ferment. It is different from the method.
More specifically, the following method can be illustrated.
First, kale and saccharide of the same amount as the amount of water contained in kale are mixed. This mixture is allowed to stand for a while, and is naturally fermented under facultative aerobic conditions by microorganisms (or resident bacteria) resident in the kale while exuding various components such as moisture and protein in the kale.
As an operation procedure for fermenting, first, fully mature kale leaves are collected, and then as pretreatment, the harvested leaves are lightly washed with water after harvesting, drained, and wounds and spoiled parts are excised in advance. To do. The kale is cut into a size of about 1 to 5 cm using a cutter or a cutter. Kale leaves cut in this way are mixed with sugar in the same amount as the amount of water contained in the kale in the fermentation vessel, loaded with cobblestone, and passed through microorganisms (resident bacteria) resident in the kale at the beginning of fermentation. Allow aerobic fermentation to occur. The saccharide mixed with the kale is preferably a saccharide mainly composed of sucrose such as brown sugar, tri-warm sugar, refined sugar, granulated sugar, and particularly preferably brown sugar. The amount of water in the kale is measured in advance or mixed with the same amount of water (equivalent to about 90%) disclosed in the 5th Food Standard Composition Table. Various components and proteins contained in kale are extracted by osmotic pressure when mixed with sugars. It is considered that these components are converted into a composition having TNF-α production promoting action by fermentation. The amount of water based on Kale's 5th standard food ingredient list is 90.2 g per 100 g. Therefore, in the case where the amount of water in kale is not measured, saccharides may be added with the aim of 90% weight of kale.
In a fermentation container, in order to maintain facultative aerobic fermentation conditions, a weight (weight) is placed on the lid and left to stand. The weight of the weight is 0.2 to 2 kg per 100 square centimeters. At the start of fermentation, agitation is performed once to several times a day, and then aerobic fermentation is continued for 2 to 10 months while maintaining a temperature of 25 to 35 ° C. In this fermentation process, fermentation by microorganisms (resident bacteria) that are resident in kale progresses simultaneously, and the kale tissue undergoes enzymatic degradation during the fermentation process, resulting in a mixture of liquid and solid viscous kale fermented products. It becomes. By filtering this fermented kale product with a wire mesh or the like, a fermented kale product having an effect of promoting TNF-α production, which is an object of the present invention, is obtained.
本発明のTNF-α産生促進活性は、TNF−α活性の産生量(TNF−α産生量)を指標として経時的に測定を行ったところ、発酵開始1ヶ月経過後にTNF−α産生量が増加し、2ヶ月経過後に活性の総量はピークに到達し、9ヶ月経過まで緩やかに減少してゆくことが下記に示す試験例によって判明している。したがって最も効率よくTNF−α産生促進剤を生産するためには、実施例に示すように発酵期間を2ヶ月とすることが好ましい。
なおTNF−α活性の測定は、市販のTNF−α抗体を用いたエンザイムイムノアッセイ法によって容易に測定可能である。
この測定方法は、マクロファージに分化する細胞であるマウスリンパ球由来細胞株RAW264.7(ATTC社製)を10% ウシ胎児血清(FBS)を含むDulbecco’s Modified Eagle Medium(DMEM,GIBCO BRL社製)に分散し、105個/wellの割合で24wellプレート(Nunc社製)に播種し、培養した細胞培養系に被験試料を添加すると、TNF−α産生促進作用を有する物質は、RAW264.7をマクロファージ様細胞に分化増殖させるとともに、TNF−αを培養液中に産生させることを利用するものである。そして細胞培養液中のTNF−α量は、上記のとおりTNF−α抗体を用いたエンザイムイムノアッセイ法によって測定する。
The TNF-α production promoting activity of the present invention was measured over time using the production amount of TNF-α activity (TNF-α production amount) as an index. As a result, the TNF-α production amount increased after one month from the start of fermentation. It has been found from the following test examples that the total amount of activity reaches a peak after 2 months and gradually decreases until 9 months. Therefore, in order to produce the TNF-α production promoter most efficiently, it is preferable to set the fermentation period to 2 months as shown in the Examples.
The measurement of TNF-α activity can be easily performed by an enzyme immunoassay method using a commercially available TNF-α antibody.
In this measurement method, a mouse lymphocyte-derived cell line RAW264.7 (manufactured by ATTC), which is a cell that differentiates into macrophages, is added to Dulbecco's Modified Eagle Medium (DMEM, GIBCO BRL) containing 10% fetal bovine serum (FBS). ), Seeded on a 24-well plate (manufactured by Nunc) at a rate of 10 5 / well, and a test sample added to the cultured cell culture system, the substance having a TNF-α production promoting action is RAW 264.7. Is differentiated into macrophage-like cells and TNF-α is produced in the culture medium. Then, the amount of TNF-α in the cell culture medium is measured by an enzyme immunoassay method using a TNF-α antibody as described above.
発酵に伴ってTNF−α産生量が上昇し、所期の想定値に到達した時点で発酵終了とする。目途とする発酵期間は25℃で約2ヶ月程度である。発酵終了後、粗大な固形物をろ過し除去したケール発酵物は、そのまま、あるいはさらに遠心分離操作などの固液分離を行って、得られた沈殿部分をTNF−α産生促進剤とすることができる。また、TNF−α産生促進剤とするため、発酵物は、各種方法で乾燥させ、乾燥物とすることが取り扱い上好ましい。発酵物中のTNF−α産生促進活性は、主として遠心分離によって沈殿する固体部分に存在するため、あらかじめ水分を精密ろ過、あるいは遠心分離により固液分離操作をおこない、液体部分を除去して、さらに乾燥させることでより効率よく、TNF−α産生促進活性を有する粉末とすることができる。乾燥は、どのような乾燥方法であっても採用することができるが、低温の凍結乾燥が特に好ましい。 When the amount of TNF-α production increases with the fermentation and reaches the expected value, the fermentation is terminated. The target fermentation period is about 2 months at 25 ° C. After the fermentation, the fermented kale obtained by removing coarse solids by filtration may be subjected to solid-liquid separation as it is or further by centrifugation, and the resulting precipitate portion may be used as a TNF-α production promoter. it can. Moreover, in order to make it a TNF- (alpha) production promoter, it is preferable on handling that a fermented material is dried by various methods, and is set as a dried material. Since the TNF-α production promoting activity in the fermented product is mainly present in the solid part that precipitates by centrifugation, the liquid part is removed by microfiltration of the water in advance or by centrifugation, and the liquid part is removed. It can be set as the powder which has TNF- (alpha) production promotion activity more efficiently by making it dry. Any drying method can be employed for drying, but low temperature freeze drying is particularly preferred.
上記で得たTNF−α産生促進活性を有する粉末は、賦形剤としてでんぷん分解物を、バインダーとして造粒することで、TNF−α産生促進活性を有する取り扱い操作のしやすい粉末とすることができる。具体的な造粒方法としては、流動層造粒、撹拌造粒、押し出し造粒などが挙げられる。本発明には、これらの造粒方法に通常用いられている装置を使用することができる。
中でも本発明には、流動層造粒が好ましく用いられる。流動層造粒は、簡便に且つ大量に造粒物を生産できることから好ましい。さらに、流動層造粒によれば、比較的低温で造粒操作を実施することができるので栄養素の破壊を抑えることができ、また、嵩密度の低い造粒物が得られ、造粒物の風味や食感をソフトにすることができ、また水溶けのよい造粒物が得られることから好ましい。
この造粒物は、ケール葉を搾汁して製造された所謂青汁の粉末と同様にして飲食することができる。例えば、カレー、シチュー、みそ汁、蒸しパン、ホットケーキ、ワッフル、クレープなどに加えて食してもよい。また、水、お湯、牛乳、果汁、豆乳などの飲料とともに服用することもできる。
さらに、賦形剤、滑沢剤などと混合し打錠成型して錠剤とすることもできる。またゼラチンやヒドロキシメチルセルロース製のカプセルに充填しカプセル剤とすることもできる。
The powder having TNF-α production promoting activity obtained above may be made into a powder having a TNF-α production promoting activity and easy to handle by granulating starch as an excipient and a binder. it can. Specific granulation methods include fluidized bed granulation, stirring granulation, extrusion granulation, and the like. The apparatus normally used for these granulation methods can be used for this invention.
Among them, fluidized bed granulation is preferably used in the present invention. Fluidized bed granulation is preferable because a granulated product can be produced easily and in large quantities. Furthermore, according to fluidized bed granulation, the granulation operation can be carried out at a relatively low temperature, so that the destruction of nutrients can be suppressed, and a granulated product having a low bulk density is obtained. The flavor and texture can be made soft, and a granulated product with good water solubility is obtained, which is preferable.
This granulated product can be eaten and eaten in the same manner as the so-called green juice powder produced by squeezing kale leaves. For example, it may be eaten in addition to curry, stew, miso soup, steamed bread, hot cake, waffle, crepe and the like. It can also be taken with beverages such as water, hot water, milk, fruit juice, and soy milk.
Furthermore, it can be mixed with excipients, lubricants and the like, and tableted to form tablets. It can also be filled into gelatin or hydroxymethylcellulose capsules to form capsules.
以下、実施例、試験例を示し本発明のTNF−α産生促進剤の製造を説明するが、本発明はこれらの実施例に限定されるものではない。
試験1.TNF−α産生促進活性の測定方法
次の操作手順によって測定する
(1)10%FBS, 10,000Unit/mL Penicillin及び10,000μg/mL Streptomycin、 200mMグルタミン酸を含むDMEM培地(以下、DMEM培地)でマウス白血病細胞株RAW264.7(ATCC社製)を37℃、5%CO2条件下で培養する。
(2)0.25%Trypsin及び1mM EDTA・4Naを含む液でRAW264.7を剥がし、遠心分離(3000rpm,5min)を行い、細胞を回収する。
(3)DMEM培地を添加し、5.0×105cells/mLになるように細胞密度を調整する。
(4)24microwell plateに400μLずつ細胞播種し37℃、5%CO2環境下で24時間インキュベートする。
(5)インキュベート後、各ウェルのDMEM培地を吸引除去する。
(6)次いで、各ウェルに10,000Unit/mL Penicillin、 10,000Unit/mL Streptomycinを含むRPMI1640培地を495μL、及び各測定サンプルを5μL添加し、37℃、5%CO2環境下で24時間インキュベートする。
(7)上澄みを回収し、TNF−α ELISA kit(Thermo Scientific社製)を使用してTNF−α産生量を測定する。
(8)試験試料無添加の細胞(対照)のTNF−α産生量と比較し、対照(試料無添加)と比較して増加したTNF−α活性をTNF−α産生促進活性とする。
Hereinafter, although an Example and a test example are shown and manufacture of the TNF- (alpha) production promoter of this invention is demonstrated, this invention is not limited to these Examples.
(2) RAW264.7 is peeled off with a solution containing 0.25% Trypsin and 1 mM EDTA · 4Na, and centrifuged (3000 rpm, 5 min) to collect cells.
(3) DMEM medium is added and the cell density is adjusted to 5.0 × 10 5 cells / mL.
(4) 400 μL of cells are seeded in a 24 microwell plate and incubated at 37 ° C. in a 5% CO 2 environment for 24 hours.
(5) After incubation, aspirate the DMEM medium in each well.
(6) Next, 495 μL of RPMI1640 medium containing 10,000 Unit / mL Penicillin and 10,000 Unit / mL Streptomycin and 5 μL of each measurement sample were added to each well, and incubated at 37 ° C. in a 5% CO 2 environment for 24 hours. To do.
(7) The supernatant is collected, and the amount of TNF-α produced is measured using a TNF-α ELISA kit (manufactured by Thermo Scientific).
(8) The TNF-α production increased compared to the control (no sample added) compared to the TNF-α production amount of the cells without the test sample added (control) is defined as the TNF-α production promoting activity.
試験2.ケール発酵方法
ケールの発酵は次のとおり実施した。
(1)ケールの葉5.1kgを水で洗浄し、よく水を切る。
(2)裁断機で約5cmに裁断する。
(3)黒糖4.6kgを添加し、良く混合する。
(4)プラスチック製容器(漬物樽)に入れ、蓋をし、蓋の上に6kgの重石を載せ、25℃で静置し自然発酵させる。
(1) Wash 5.1 kg of kale leaves with water and drain thoroughly.
(2) Cut to about 5 cm with a cutter.
(3) Add 4.6 kg of brown sugar and mix well.
(4) Put in a plastic container (pickled barrel), put a lid,
試験3.発酵期間とTNF−α産生促進活性の変化
発酵開始から1ヶ月、2ヶ月、6ヶ月、9ヶ月経過後に発酵物の固液混合物から液体部分を採取し、これを、試験試料とした。上記の1に記載の手法でTNF−α活性を測定し、これを試験試料1mLあたりのTNF−αの産生量に換算し、TNF−α促進活性とした。TNF−α産生促進活性量の変化を図1に示す。
Test 3. Changes in fermentation period and TNF-α production promoting activity After 1 month, 2 months, 6 months and 9 months from the start of fermentation, a liquid part was collected from the solid-liquid mixture of the fermented product, and this was used as a test sample. The TNF-α activity was measured by the method described in 1 above, and this was converted into the amount of TNF-α produced per 1 mL of the test sample to obtain TNF-α promoting activity. Changes in the TNF-α production promoting activity amount are shown in FIG.
TNF−α産生促進活性量は、発酵1ヶ月は、低値(244pg/mL)であったが、2ヶ月目に急上昇し(1768pg/mL)となった。その後緩やかに低下し、発酵開始から9ヶ月後は約1512pg/mLとなった。 The amount of TNF-α production promoting activity was low (244 pg / mL) in the first month of fermentation, but rapidly increased (1768 pg / mL) in the second month. After that, it gradually decreased and became about 1512 pg / mL after 9 months from the start of fermentation.
試験4.最適発酵条件の確認試験
試験3により、発酵期間中もっともTNF−α産生促進活性が高まる時期は、発酵開始から2ヶ月目であることが明らかとなった。この期間中に、発酵環境がどのような変化を示すのか確認するため、試験2と同様に発酵物を調製し、発酵開始1ヶ月目、1.5ヶ月目、2ヶ月目の3時点で、TNF−α産生促進活性量、pH変化、微生物相の変化を観察した。微生物相の変化は、標準寒天培地、BCP加プレートカウントアガール培地、ポテトデキストロース寒天培地を用いて発酵物1mL当たりの一般細菌数、乳酸菌数、真菌(酵母)数の変化を測定した。
TNF−α産生促進活性の変化を図2に示した。またTNF−α産生促進活性、pH変化、微生物相の測定結果を一括して下記の表1に示した。
Test 4. Test for Confirmation of Optimum Fermentation Condition Test 3 revealed that the time when the TNF-α production promoting activity was most enhanced during the fermentation period was the second month from the start of fermentation. During this period, in order to confirm what kind of change the fermentation environment shows, a fermented material is prepared in the same manner as in
Changes in TNF-α production promoting activity are shown in FIG. Table 1 below collectively shows the measurement results of TNF-α production promoting activity, pH change, and microflora.
図2から、TNF−α産生促進活性は、発酵開始1.5ヶ月から2ヶ月の間で3倍に増加することが確認できた。したがってTNF−α産生促進剤を得るためには、ケールと糖類からなる混合物を最低2ヶ月間発酵させることが必要であることが明らかとなった。
一方pHは、pH4.17からpH3.89まで低下していることがわかった。また微生物相は、発酵開始直後1ヶ月目の菌叢を1.5ヶ月、2ヶ月目も維持していたが菌数は減少していた。菌数の減少は発酵にともなう菌体のオートリシスによるものと推測される。
この試験からTNF−α産生促進活性は、発酵期間とpHの管理が重要であることが予想された。
From FIG. 2, it was confirmed that the TNF-α production promoting activity increased three-fold between 1.5 months and 2 months from the start of fermentation. Therefore, in order to obtain a TNF-α production promoter, it became clear that it was necessary to ferment a mixture of kale and saccharides for at least 2 months.
On the other hand, it was found that the pH was lowered from pH 4.17 to pH 3.89. The microflora maintained the bacterial flora of the first month immediately after the start of fermentation for 1.5 months and 2 months, but the number of bacteria decreased. The decrease in the number of bacteria is presumed to be due to the autolysis of the cells accompanying fermentation.
From this test, it was predicted that the control of the fermentation period and pH was important for the TNF-α production promoting activity.
試験5.発酵物中のTNF−α産生促進活性の存在状態の確認試験
試験4で得た発酵2ヶ月経過後の発酵物中に存在するTNF−α産生促進活性の存在状態を確認するために以下の試験を行った。
発酵開始2ヶ月経過した容器から内容物を取り出し、これを目の細かな金網を用いてろ過し、ろ過液を回収した。この液を用いて試験を行った。なお、ろ過済みの発酵ろ過液を、以下の試験では発酵エキス(A)と呼ぶ。
発酵エキス1.0mLを10,000rpmで10分間遠心分離し、上清(上澄み)と沈殿物の2層に分離させた。次いで上清を、ピペットで回収した。回収した上清は、0.984mLであった。
次いで、この上清を0.45μmのミリポアフィルターを用いて精密ろ過し、この精密ろ過液(B)を試料として試験1の方法でTNF−α産生活性を測定した。
また遠心分離して沈殿した沈殿残渣分画は、別に回収した。そして0.984mLになるように精製水を添加し、これを同様にTNF−α産生活性測定試料(C)とした。
以上の操作手順を模式図として図3に示す。
精密ろ過液(B)及び沈殿残渣(B)のTNF−α産生活性測定結果は、発酵エキス(A)の活性を100%とした相対値で表した。結果を図3に示す。
図4の結果から、発酵物中のTNF−α産生活性は、上清(B)には殆ど存在せず、沈殿残渣分画(C)に存在することが確認できた。TNF−α産生促進活性は、水に不溶の状態で発酵物中に存在することが予想された。
Test 5. Confirmation test of existence state of TNF-α production promoting activity in fermented product The following test was conducted to confirm the existence state of TNF-α production promoting activity present in the fermented product after 2 months of fermentation obtained in Test 4 Went.
The contents were taken out from the
1.0 mL of the fermented extract was centrifuged at 10,000 rpm for 10 minutes, and separated into two layers of a supernatant (supernatant) and a precipitate. The supernatant was then collected with a pipette. The collected supernatant was 0.984 mL.
Subsequently, the supernatant was microfiltered using a 0.45 μm Millipore filter, and the TNF-α production activity was measured by the method of
In addition, the fraction of precipitate residue precipitated by centrifugation was collected separately. And purified water was added so that it might become 0.984 mL, and this was made into the TNF- (alpha) production activity measurement sample (C) similarly.
The above operation procedure is shown in FIG. 3 as a schematic diagram.
The TNF-α production activity measurement results of the microfiltrate (B) and the precipitation residue (B) were expressed as relative values with the activity of the fermentation extract (A) as 100%. The results are shown in FIG.
From the results of FIG. 4, it was confirmed that the TNF-α production activity in the fermented product was hardly present in the supernatant (B) but present in the precipitate residue fraction (C). The TNF-α production promoting activity was expected to be present in the fermented product in an insoluble state in water.
Claims (3)
1)ケール葉を常在菌が残留するように軽度に水洗する工程
2)ケール葉を裁断する工程
3)ケール葉の水分量に相当する質量の糖類と混合し、好気性〜通性嫌気性条件で発酵させる工程
4)発酵終了後、固形物をろ過して除去し、TNF−α産生促進活性を有するろ過液を回収する工程
5)遠心分離を行い、沈殿物を回収する工程
The manufacturing method of the TNF- (alpha) production promoter which consists of the following process.
1) Step of washing the kale leaf with light so that resident bacteria remain 2) Step of cutting the kale leaf 3) Mixing with a saccharide having a mass corresponding to the water content of the kale leaf, aerobic to facultative anaerobic Step of fermenting under conditions 4) Step of recovering a filtrate having TNF-α production promoting activity by filtering and removing solid matter after completion of fermentation.
5) Step of collecting precipitates by centrifugation
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015171689A JP6616631B2 (en) | 2015-09-01 | 2015-09-01 | TNF-α production promoter |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015171689A JP6616631B2 (en) | 2015-09-01 | 2015-09-01 | TNF-α production promoter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017048137A JP2017048137A (en) | 2017-03-09 |
JP6616631B2 true JP6616631B2 (en) | 2019-12-04 |
Family
ID=58279153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015171689A Active JP6616631B2 (en) | 2015-09-01 | 2015-09-01 | TNF-α production promoter |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6616631B2 (en) |
-
2015
- 2015-09-01 JP JP2015171689A patent/JP6616631B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017048137A (en) | 2017-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108354096B (en) | Collagen compound beverage for resisting wrinkles, preserving moisture and improving skin elasticity | |
KR101980477B1 (en) | Method for producing Makgeolli using silver skin of coffee | |
JP2008067680A (en) | Lactic acid solution prepared by distillation and soybean fermentation and method for producing yoghurt-like food | |
CN104780987A (en) | Extraction method | |
CN107099428A (en) | A kind of method that utilization cyperue esculentus dregs of rice manufacture cyperue esculentus polypeptide fruit wine | |
CN107242295B (en) | Preparation method of purple sweet potato yoghourt | |
CN102719341A (en) | Red date wine and preparation method thereof | |
TWI702005B (en) | Pea extract and its use | |
CN104726285A (en) | Proanthocyanidins-rich health liquor and making method thereof | |
CN104480150A (en) | Biological enrichment method of conjugated linolenic acid isomer | |
CN101756237B (en) | Method for producing Pinctada martensii meat antihypertensive functional nutrient solution | |
US3780183A (en) | Plant protein product and process | |
JP6616631B2 (en) | TNF-α production promoter | |
CN101006849B (en) | Durian extract, preparing process and application thereof | |
CN102373133A (en) | Formula and production technology of organic fig wine | |
KR101515253B1 (en) | Agent for promoting the secretion of and/or suppressing decrease of adiponectin | |
JP4662276B2 (en) | Shochu, fermented products, food and drink, feed and methods for producing them | |
JPH0919269A (en) | Production of food or beverage containing fruit body of hericium erinaceum | |
JP2004154035A (en) | Method for producing lactobacillus fermented food product, lactobacillus fermented food product and defecation improver both obtained by the method | |
CN108840903A (en) | A kind of extracting method of rice protein powder | |
CN106213470B (en) | A method of fermentation acidic juice reduces acrylamide in high-temperature processed food and generates | |
CN110506877B (en) | Preparation method of dried orange peel flavored fermented beverage | |
CN108504488A (en) | Whey wine and preparation method thereof | |
JPH0919270A (en) | Production of food or beverage containing cultured mycelia of hericium erinaceum | |
CN107467639A (en) | A kind of coproduction prepares oat beta glucan nutrient powder and the method for dietary fiber micro powder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180607 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190225 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190517 Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190517 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191029 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191108 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6616631 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |